You are here

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Last updated on October 12, 2019

FOR MORE INFORMATION
Study Location
Tucson, Arizona, 85404 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acute Myeloid Leukemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Treated by Mylotarg

- Provide ICF

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Treated by Mylotarg

- Provide ICF

NCT00161668
Pfizer
Completed
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Acute Myeloid Leukemia
NCT02038777
All Genders
20+
Years
Multiple Sites
Descriptive Information
Brief TitleStudy Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Official TitleProspective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Brief SummaryThis study is designed to assess the safety of Mylotarg therapy in routine practice.
Detailed DescriptionNot Provided
Study TypeObservational
Study DesignObservational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNot Provided
Study PopulationNot Provided
ConditionAcute Myeloid Leukemia
InterventionDrug: Mylotarg
Study Groups/CohortsNot Provided
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Enrollment
 (submitted: September 11, 2005)
500
Original EnrollmentSame as current
Study Completion DateNot Provided
Primary Completion DateNot Provided
Eligibility Criteria

Inclusion Criteria:

  • Treated by Mylotarg
  • Provide ICF
Sex/Gender
Sexes Eligible for Study:All
Ages18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesUnited States
Removed Location Countries  
 
Administrative Information
NCT NumberNCT00161668
Other Study ID Numbers0903X-100847
Has Data Monitoring CommitteeNot Provided
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyNot Provided
Study SponsorWyeth is now a wholly owned subsidiary of Pfizer
CollaboratorsNot Provided
Investigators
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS AccountWyeth is now a wholly owned subsidiary of Pfizer
Verification DateMarch 2007

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now